Piper Sandler analyst David Westenberg lowered the firm’s price target on GeneDx (WGS) to $130 from $160 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- Genedx Holdings Warned of Potential Goodwill and Intangible Asset Impairments That Could Hit Earnings
- GeneDx: Attractive Entry Point on Rebased Valuation and Robust 2026 Growth Outlook
- GeneDx price target lowered to $150 from $180 at Jefferies
- Morning Movers: Arcellx skyrockets following pact to be acquired
- GeneDx reports Q4 adjusted EPS 14c, consensus 12c